Toxicity of phosphate enemas - an updated review

Enemas containing phosphate are widely prescribed and may cause important adverse effects. A systemic review published in 2007 reported the literature on the adverse effects of phosphate enemas from January 1957 to March 2007 and identified 12 deaths. These were thought due to electrolyte disturbanc...

Full description

Saved in:
Bibliographic Details
Published inClinical toxicology (Philadelphia, Pa.) Vol. 60; no. 6; pp. 672 - 680
Main Authors Hamilton Smith, Rosa, Eddleston, Michael, Bateman, D. Nicholas
Format Journal Article
LanguageEnglish
Published England Taylor & Francis 03.06.2022
Subjects
Online AccessGet full text
ISSN1556-3650
1556-9519
1556-9519
DOI10.1080/15563650.2022.2054424

Cover

Abstract Enemas containing phosphate are widely prescribed and may cause important adverse effects. A systemic review published in 2007 reported the literature on the adverse effects of phosphate enemas from January 1957 to March 2007 and identified 12 deaths. These were thought due to electrolyte disturbances, heart failure and kidney injury. These data raised concerns about the use of phosphate enemas in routine practice. Newer osmotic-based enema alternatives are now available that do not contain absorbable ions. We sought to review the literature since this review and evaluate the latest data on the toxicity of phosphate-containing enemas. To gain a fuller picture we included case series and larger studies as well as case reports. To review the toxicity of phosphate enemas, particularly with respect to acute metabolic consequences and their associated clinical features. To identify risk factors for metabolic toxicity and consider whether phosphate enemas should be relatively contra-indicated in specific patient groups. A systematic literature review was conducted in PubMed, Google Scholar, and Cochrane Reviews (2005-2021) using the search terms 'phosphate enema or sodium phosphate enema' or 'phosphate-based enema' or (phosphate AND enema) or (Fleet AND enema) or 'sodium phosphate laxatives' or 'sodium phosphate catharsis' or 'sodium phosphate cathartic'. Relevant papers were read, and data were extracted. The searches identified 489 papers of which 25 were relevant: seven papers were case reports or small case series of metabolic abnormalities from the use of phosphate enemas in nine children, six were case reports on 16 adults. Nine papers were large case series or clinical studies that included data on systemic metabolic effects, of varying size from 24 healthy volunteers to a cohort of 70,499 patients. Case reports identified seven adult deaths but none in children. Children most often presented with decreased consciousness (6/9), and tetany (4/9). In adults overall only five cases had clinical features reported, hypotension was seen in four and QT prolongation in two. Treatment was generally symptomatic, with intravenous fluid and calcium salts for electrolyte changes and hypocalcaemia, and vasopressors for severe hypotension. Haemodialysis was used in three children and peritoneal dialysis in one, all of whom survived. In adults, haemodialysis did not prevent death in two of four cases in whom it was used. Common factors underlying toxicity were inappropriately high phosphate dose, or enema retention, both resulting in greater absorption of phosphate. Associated pre-disposing conditions included Hirschsprung disease in children and co-morbidity and renal impairment (2/5) in older adults. Absolute reported changes in serum phosphate or calcium were not accurate indicators of outcome. Larger case series and clinical trials confirm an acute effect of phosphate enemas on serum phosphate, which was related to both dose and retention time. These effects were not seen with non-phosphate preparations. In these cases series, adverse events were rarely reported. Phosphate enemas are potentially toxic, particularly in young children with Hirschsprung disease and in the elderly with co-morbidity. Raised awareness of the risk of phosphate enemas is still required. Other less toxic enema preparations are available and should be considered in patients at extremes of age. If phosphate enemas are the only clinical option careful monitoring of biochemical sequelae should be undertaken.
AbstractList Enemas containing phosphate are widely prescribed and may cause important adverse effects. A systemic review published in 2007 reported the literature on the adverse effects of phosphate enemas from January 1957 to March 2007 and identified 12 deaths. These were thought due to electrolyte disturbances, heart failure and kidney injury. These data raised concerns about the use of phosphate enemas in routine practice. Newer osmotic-based enema alternatives are now available that do not contain absorbable ions. We sought to review the literature since this review and evaluate the latest data on the toxicity of phosphate-containing enemas. To gain a fuller picture we included case series and larger studies as well as case reports. To review the toxicity of phosphate enemas, particularly with respect to acute metabolic consequences and their associated clinical features. To identify risk factors for metabolic toxicity and consider whether phosphate enemas should be relatively contra-indicated in specific patient groups. A systematic literature review was conducted in PubMed, Google Scholar, and Cochrane Reviews (2005-2021) using the search terms 'phosphate enema or sodium phosphate enema' or 'phosphate-based enema' or (phosphate AND enema) or (Fleet AND enema) or 'sodium phosphate laxatives' or 'sodium phosphate catharsis' or 'sodium phosphate cathartic'. Relevant papers were read, and data were extracted. The searches identified 489 papers of which 25 were relevant: seven papers were case reports or small case series of metabolic abnormalities from the use of phosphate enemas in nine children, six were case reports on 16 adults. Nine papers were large case series or clinical studies that included data on systemic metabolic effects, of varying size from 24 healthy volunteers to a cohort of 70,499 patients. Case reports identified seven adult deaths but none in children. Children most often presented with decreased consciousness (6/9), and tetany (4/9). In adults overall only five cases had clinical features reported, hypotension was seen in four and QT prolongation in two. Treatment was generally symptomatic, with intravenous fluid and calcium salts for electrolyte changes and hypocalcaemia, and vasopressors for severe hypotension. Haemodialysis was used in three children and peritoneal dialysis in one, all of whom survived. In adults, haemodialysis did not prevent death in two of four cases in whom it was used. Common factors underlying toxicity were inappropriately high phosphate dose, or enema retention, both resulting in greater absorption of phosphate. Associated pre-disposing conditions included Hirschsprung disease in children and co-morbidity and renal impairment (2/5) in older adults. Absolute reported changes in serum phosphate or calcium were not accurate indicators of outcome. Larger case series and clinical trials confirm an acute effect of phosphate enemas on serum phosphate, which was related to both dose and retention time. These effects were not seen with non-phosphate preparations. In these cases series, adverse events were rarely reported. Phosphate enemas are potentially toxic, particularly in young children with Hirschsprung disease and in the elderly with co-morbidity. Raised awareness of the risk of phosphate enemas is still required. Other less toxic enema preparations are available and should be considered in patients at extremes of age. If phosphate enemas are the only clinical option careful monitoring of biochemical sequelae should be undertaken.
Enemas containing phosphate are widely prescribed and may cause important adverse effects. A systemic review published in 2007 reported the literature on the adverse effects of phosphate enemas from January 1957 to March 2007 and identified 12 deaths. These were thought due to electrolyte disturbances, heart failure and kidney injury. These data raised concerns about the use of phosphate enemas in routine practice. Newer osmotic-based enema alternatives are now available that do not contain absorbable ions. We sought to review the literature since this review and evaluate the latest data on the toxicity of phosphate-containing enemas. To gain a fuller picture we included case series and larger studies as well as case reports.INTRODUCTIONEnemas containing phosphate are widely prescribed and may cause important adverse effects. A systemic review published in 2007 reported the literature on the adverse effects of phosphate enemas from January 1957 to March 2007 and identified 12 deaths. These were thought due to electrolyte disturbances, heart failure and kidney injury. These data raised concerns about the use of phosphate enemas in routine practice. Newer osmotic-based enema alternatives are now available that do not contain absorbable ions. We sought to review the literature since this review and evaluate the latest data on the toxicity of phosphate-containing enemas. To gain a fuller picture we included case series and larger studies as well as case reports.To review the toxicity of phosphate enemas, particularly with respect to acute metabolic consequences and their associated clinical features. To identify risk factors for metabolic toxicity and consider whether phosphate enemas should be relatively contra-indicated in specific patient groups.OBJECTIVESTo review the toxicity of phosphate enemas, particularly with respect to acute metabolic consequences and their associated clinical features. To identify risk factors for metabolic toxicity and consider whether phosphate enemas should be relatively contra-indicated in specific patient groups.A systematic literature review was conducted in PubMed, Google Scholar, and Cochrane Reviews (2005-2021) using the search terms 'phosphate enema or sodium phosphate enema' or 'phosphate-based enema' or (phosphate AND enema) or (Fleet AND enema) or 'sodium phosphate laxatives' or 'sodium phosphate catharsis' or 'sodium phosphate cathartic'. Relevant papers were read, and data were extracted.METHODSA systematic literature review was conducted in PubMed, Google Scholar, and Cochrane Reviews (2005-2021) using the search terms 'phosphate enema or sodium phosphate enema' or 'phosphate-based enema' or (phosphate AND enema) or (Fleet AND enema) or 'sodium phosphate laxatives' or 'sodium phosphate catharsis' or 'sodium phosphate cathartic'. Relevant papers were read, and data were extracted.The searches identified 489 papers of which 25 were relevant: seven papers were case reports or small case series of metabolic abnormalities from the use of phosphate enemas in nine children, six were case reports on 16 adults. Nine papers were large case series or clinical studies that included data on systemic metabolic effects, of varying size from 24 healthy volunteers to a cohort of 70,499 patients. Case reports identified seven adult deaths but none in children. Children most often presented with decreased consciousness (6/9), and tetany (4/9). In adults overall only five cases had clinical features reported, hypotension was seen in four and QT prolongation in two. Treatment was generally symptomatic, with intravenous fluid and calcium salts for electrolyte changes and hypocalcaemia, and vasopressors for severe hypotension. Haemodialysis was used in three children and peritoneal dialysis in one, all of whom survived. In adults, haemodialysis did not prevent death in two of four cases in whom it was used. Common factors underlying toxicity were inappropriately high phosphate dose, or enema retention, both resulting in greater absorption of phosphate. Associated pre-disposing conditions included Hirschsprung disease in children and co-morbidity and renal impairment (2/5) in older adults. Absolute reported changes in serum phosphate or calcium were not accurate indicators of outcome. Larger case series and clinical trials confirm an acute effect of phosphate enemas on serum phosphate, which was related to both dose and retention time. These effects were not seen with non-phosphate preparations. In these cases series, adverse events were rarely reported.RESULTSThe searches identified 489 papers of which 25 were relevant: seven papers were case reports or small case series of metabolic abnormalities from the use of phosphate enemas in nine children, six were case reports on 16 adults. Nine papers were large case series or clinical studies that included data on systemic metabolic effects, of varying size from 24 healthy volunteers to a cohort of 70,499 patients. Case reports identified seven adult deaths but none in children. Children most often presented with decreased consciousness (6/9), and tetany (4/9). In adults overall only five cases had clinical features reported, hypotension was seen in four and QT prolongation in two. Treatment was generally symptomatic, with intravenous fluid and calcium salts for electrolyte changes and hypocalcaemia, and vasopressors for severe hypotension. Haemodialysis was used in three children and peritoneal dialysis in one, all of whom survived. In adults, haemodialysis did not prevent death in two of four cases in whom it was used. Common factors underlying toxicity were inappropriately high phosphate dose, or enema retention, both resulting in greater absorption of phosphate. Associated pre-disposing conditions included Hirschsprung disease in children and co-morbidity and renal impairment (2/5) in older adults. Absolute reported changes in serum phosphate or calcium were not accurate indicators of outcome. Larger case series and clinical trials confirm an acute effect of phosphate enemas on serum phosphate, which was related to both dose and retention time. These effects were not seen with non-phosphate preparations. In these cases series, adverse events were rarely reported.Phosphate enemas are potentially toxic, particularly in young children with Hirschsprung disease and in the elderly with co-morbidity. Raised awareness of the risk of phosphate enemas is still required. Other less toxic enema preparations are available and should be considered in patients at extremes of age. If phosphate enemas are the only clinical option careful monitoring of biochemical sequelae should be undertaken.CONCLUSIONPhosphate enemas are potentially toxic, particularly in young children with Hirschsprung disease and in the elderly with co-morbidity. Raised awareness of the risk of phosphate enemas is still required. Other less toxic enema preparations are available and should be considered in patients at extremes of age. If phosphate enemas are the only clinical option careful monitoring of biochemical sequelae should be undertaken.
Author Hamilton Smith, Rosa
Bateman, D. Nicholas
Eddleston, Michael
Author_xml – sequence: 1
  givenname: Rosa
  surname: Hamilton Smith
  fullname: Hamilton Smith, Rosa
  organization: Stirling High School
– sequence: 2
  givenname: Michael
  orcidid: 0000-0002-6857-3441
  surname: Eddleston
  fullname: Eddleston, Michael
  organization: National Poisons Information Service - Edinburgh, Royal Infirmary of Edinburgh
– sequence: 3
  givenname: D. Nicholas
  orcidid: 0000-0002-8971-862X
  surname: Bateman
  fullname: Bateman, D. Nicholas
  organization: Pharmacology, Toxicology & Therapeutics, Centre for Cardiovascular Science, University of Edinburgh
BackLink https://www.ncbi.nlm.nih.gov/pubmed/35510830$$D View this record in MEDLINE/PubMed
BookMark eNqFkMlOwzAURS1URAf4BFCWbFI8JrHYgComqRKbsracxFGNEjvYCaV_j6OmLFjAxsPTuVd6Zw4mxhoFwCWCSwQzeIMYS0jC4BJDjMPBKMX0BMyGecwZ4pPxPUBTMPf-HUKSUY7OwJQwFkoInAG4sV-60N0-slXUbq1vt7JTkTKqkT6KI2mivi3DqIyc-tRqdw5OK1l7dTHeC_D2-LBZPcfr16eX1f06LigiXSxpqfI8RYgrwrIyoyh8CSVSpixTKUoZLROWpJBTDHPMCiYrnnHIMQyMqsgCXB96W2c_euU70WhfqLqWRtneC5wkEEGUJllAr0a0zxtVitbpRrq9OG4ZAHYACme9d6r6QRAUg01xtCkGm2K0GXK3v3LBlOy0NZ2Tuv43fXdIa1NZ18iddXUpOrmvraucNIX2gvxd8Q2A8YpW
CitedBy_id crossref_primary_10_3390_children11030349
crossref_primary_10_53126_MEB43649
Cites_doi 10.1016/j.jconrel.2015.04.040
10.1177/000992280504400114
10.2147/IJGM.S44417
10.1055/s-0035-1548839
10.1093/qjmed/hcx165
10.1007/s10620-005-2780-9
10.1016/j.curtheres.2006.10.004
10.3238/arztebl.2015.0781
10.1007/s00467-010-1570-6
10.4067/S0370-41062017000300011
10.1042/CS20100377
10.1007/s00414-009-0344-9
10.1002/14651858.CD000330.pub3
10.2169/internalmedicine.47.0704
10.1097/PEC.0b013e31823b0088
10.5414/CN110345
10.1016/j.jemermed.2019.07.009
10.1111/jgs.13588
10.1007/s00383-012-3124-4
10.1001/archinternmed.2011.694
10.1007/s00431-009-0999-8
10.1111/ans.16360
10.1007/s00431-008-0705-2
10.1097/SGA.0b013e3181e26ec2
10.1373/clinchem.2011.170183
10.1111/j.1365-2036.2007.03354.x
10.1053/j.ajkd.2015.11.018
10.1097/PEC.0000000000000267
ContentType Journal Article
Copyright 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group 2022
Copyright_xml – notice: 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group 2022
DBID 0YH
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1080/15563650.2022.2054424
DatabaseName Taylor & Francis Open Access
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE
MEDLINE - Academic

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 3
  dbid: 0YH
  name: Taylor & Francis Open Access
  url: https://www.tandfonline.com
  sourceTypes: Publisher
DeliveryMethod fulltext_linktorsrc
Discipline Public Health
EISSN 1556-9519
EndPage 680
ExternalDocumentID 35510830
10_1080_15563650_2022_2054424
2054424
Genre Review
Systematic Review
Journal Article
GroupedDBID ---
00X
03L
0BK
0R~
0YH
29B
36B
4.4
5RE
AALUX
AAMIU
AAPUL
AAQRR
ABBKH
ABDBF
ABEIZ
ABJNI
ABLIJ
ABLKL
ABUPF
ABXYU
ACENM
ACGFS
ACIEZ
ACUHS
ADCVX
ADRBQ
AECIN
AENEX
AEOZL
AFKVX
AGDLA
AGFJD
AGRBW
AGYJP
AIJEM
AIRBT
AJWEG
AKBVH
ALMA_UNASSIGNED_HOLDINGS
ALQZU
ALYBC
BABNJ
BLEHA
BOHLJ
CCCUG
DKSSO
DU5
EAP
EAS
EBC
EBD
EBS
EDH
EHN
EMB
EMK
EMOBN
EPL
EPT
ESX
F5P
H13
HZ~
KRBQP
KSSTO
KWAYT
KYCEM
LJTGL
M4Z
O9-
Q~Q
RNANH
RVRKI
SV3
TBQAZ
TDBHL
TERGH
TFDNU
TFL
TFW
TUROJ
TUS
UHWXJ
V1S
~1N
AAGDL
AAYXX
ABWVI
ADYSH
AFRVT
AMPGV
CITATION
.GJ
34G
39C
3O-
53G
5VS
AALIY
ABCRQ
ACKYO
AGAFX
AJEBJ
AWYRJ
CAG
CGR
COF
CUY
CVF
DEIEU
DTRLO
DZHFC
ECM
EIF
EJD
LSO
M44
NPM
NUSFT
QRXOQ
7X8
TASJS
ID FETCH-LOGICAL-c413t-a4debb7119e358d841ebb343aa758e71754d656709420b25c5af98909203aaef3
IEDL.DBID 0YH
ISSN 1556-3650
1556-9519
IngestDate Sun Aug 24 03:46:52 EDT 2025
Wed Feb 19 02:26:02 EST 2025
Tue Jul 01 03:38:12 EDT 2025
Thu Apr 24 22:50:24 EDT 2025
Wed Dec 25 09:07:11 EST 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 6
Keywords toxicity
enemas
Phosphate
hyperphosphataemia
Language English
License open-access: http://creativecommons.org/licenses/by-nc-nd/4.0/: This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c413t-a4debb7119e358d841ebb343aa758e71754d656709420b25c5af98909203aaef3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
ORCID 0000-0002-6857-3441
0000-0002-8971-862X
OpenAccessLink https://www.tandfonline.com/doi/abs/10.1080/15563650.2022.2054424
PMID 35510830
PQID 2660101768
PQPubID 23479
PageCount 9
ParticipantIDs pubmed_primary_35510830
proquest_miscellaneous_2660101768
informaworld_taylorfrancis_310_1080_15563650_2022_2054424
crossref_citationtrail_10_1080_15563650_2022_2054424
crossref_primary_10_1080_15563650_2022_2054424
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2022-06-03
PublicationDateYYYYMMDD 2022-06-03
PublicationDate_xml – month: 06
  year: 2022
  text: 2022-06-03
  day: 03
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
PublicationTitle Clinical toxicology (Philadelphia, Pa.)
PublicationTitleAlternate Clin Toxicol (Phila)
PublicationYear 2022
Publisher Taylor & Francis
Publisher_xml – name: Taylor & Francis
References Muller-Lissner SA (CIT0003) 2010; 07
CIT0030
CIT0010
Marek I (CIT0014) 2015; 227
CIT0032
CIT0031
CIT0012
CIT0034
CIT0011
CIT0033
Núñez Sánchez MJ (CIT0015) 2017; 88
CIT0013
Carl I (CIT0018) 2007; 76
CIT0035
CIT0016
Yu M (CIT0009) 2015; 167
CIT0017
Caswell M. (CIT0025) 2009; 107
CIT0021
CIT0020
CIT0001
CIT0023
CIT0022
Kosseifi S (CIT0019) 2008; 106
CIT0002
CIT0024
CIT0005
CIT0027
CIT0004
CIT0026
CIT0007
CIT0029
CIT0006
CIT0028
CIT0008
References_xml – ident: CIT0001
  doi: 10.1016/j.jconrel.2015.04.040
– ident: CIT0017
  doi: 10.1177/000992280504400114
– volume: 07
  start-page: 1
  year: 2010
  ident: CIT0003
  publication-title: BMJ Clin Evid
– ident: CIT0032
  doi: 10.2147/IJGM.S44417
– volume: 227
  start-page: 235
  year: 2015
  ident: CIT0014
  publication-title: Klin Padiatr
  doi: 10.1055/s-0035-1548839
– ident: CIT0034
  doi: 10.1093/qjmed/hcx165
– ident: CIT0006
– volume: 107
  start-page: 28
  issue: 1
  year: 2009
  ident: CIT0025
  publication-title: J Ky Med Assoc
– ident: CIT0027
  doi: 10.1007/s10620-005-2780-9
– ident: CIT0029
  doi: 10.1016/j.curtheres.2006.10.004
– ident: CIT0035
  doi: 10.3238/arztebl.2015.0781
– ident: CIT0016
  doi: 10.1007/s00467-010-1570-6
– volume: 88
  start-page: 383
  issue: 3
  year: 2017
  ident: CIT0015
  publication-title: Rev Chil Pediatr
  doi: 10.4067/S0370-41062017000300011
– ident: CIT0002
  doi: 10.1042/CS20100377
– ident: CIT0010
  doi: 10.1007/s00414-009-0344-9
– ident: CIT0004
  doi: 10.1002/14651858.CD000330.pub3
– ident: CIT0022
  doi: 10.2169/internalmedicine.47.0704
– ident: CIT0031
  doi: 10.1097/PEC.0b013e31823b0088
– volume: 106
  start-page: 431
  issue: 9
  year: 2008
  ident: CIT0019
  publication-title: J Ky Med Assoc
– ident: CIT0023
  doi: 10.5414/CN110345
– ident: CIT0026
  doi: 10.1016/j.jemermed.2019.07.009
– ident: CIT0028
  doi: 10.1111/jgs.13588
– ident: CIT0012
  doi: 10.1007/s00383-012-3124-4
– volume: 167
  start-page: 237
  year: 2015
  ident: CIT0009
  publication-title: J Louisiana State Med Soc
– ident: CIT0020
  doi: 10.1001/archinternmed.2011.694
– ident: CIT0024
  doi: 10.1007/s00431-009-0999-8
– ident: CIT0008
  doi: 10.1111/ans.16360
– ident: CIT0011
  doi: 10.1007/s00431-008-0705-2
– ident: CIT0030
  doi: 10.1097/SGA.0b013e3181e26ec2
– ident: CIT0005
– ident: CIT0021
  doi: 10.1373/clinchem.2011.170183
– ident: CIT0007
  doi: 10.1111/j.1365-2036.2007.03354.x
– ident: CIT0033
  doi: 10.1053/j.ajkd.2015.11.018
– ident: CIT0013
  doi: 10.1097/PEC.0000000000000267
– volume: 76
  start-page: 172
  year: 2007
  ident: CIT0018
  publication-title: Ulster Med J
SSID ssj0038491
Score 2.3590899
SecondaryResourceType review_article
Snippet Enemas containing phosphate are widely prescribed and may cause important adverse effects. A systemic review published in 2007 reported the literature on the...
SourceID proquest
pubmed
crossref
informaworld
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 672
SubjectTerms Aged
Calcium
Child
Child, Preschool
Enema - adverse effects
enemas
Hirschsprung Disease - chemically induced
Humans
hyperphosphataemia
Hypotension - chemically induced
Laxatives - toxicity
Phosphate
Phosphates - toxicity
toxicity
Title Toxicity of phosphate enemas - an updated review
URI https://www.tandfonline.com/doi/abs/10.1080/15563650.2022.2054424
https://www.ncbi.nlm.nih.gov/pubmed/35510830
https://www.proquest.com/docview/2660101768
Volume 60
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3dS8MwEA-6vQgifjs_RgRfo22TbOnjpo4h6NMG-hTSJmGCtsV24J_vpWmHPow9-FjIpe1dc_e79O4XhG5MZFOIwiHhQ8MJMyIgiasiBMcXBzrhWtRVlc8vg-mcPb3ytpqwbMoqXQ5tPVFE7avd4lZJ2VbE3YWO1AqQBWR3keul4oxFbBt1IwCKrqoveJu2zpgKFnvKVD4gTqZt4lk3zZ_w9Ie8dD0ErUPRZB_tNRgSj7zRD9CWyQ7Rrt-Aw76v6AgFs_z7PQWMjXOLi0VeFguAlRhc26cqMcEqw8vCpfsa-_aVYzSfPM7up6Q5HoGkEHkqopg2STIMw9hQLrRgIVxSRpWCHMBAmsaZBrQ2hAQuCpKIp1zZWIANogDGGEtPUCfLM3OGsFJc65rNTKQsTm0MA4U14Ckh4QkN7SHWakWmDXe4O8LiQ4YNxWirTOmUKRtl9tDtSqzw5BmbBOLfKpdVvWth_REjkm6QvW7tI2GJuP8eKjP5spSAQRyTHrxMD516w60eB-AWTEmD83_c-QLtuMu6gIxeok71tTRXAFWqpF9_jH3UHY0fxpMfpVfZUw
linkProvider Taylor & Francis
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3NS8MwFA86Dwoifjs_I3iNtk2ypUcRR9Vtpw3mKaRtwgRti-vAP9-Xph3bQXbwWJqXtu8lL7-XvvcLQnc6MAmswj7hXc0J08Ijsc0iBMcXemnMU1FlVQ6GnWjMXid8slQLY9MqbQxtHFFE5avt5Lab0U1K3INvWa0AWkB4F9hiKs5YwDbRFhcQTcCY9t6jxhtTwULHmco7xMo0VTx_dbOyPq2wl_6NQau1qLeP9moQiR-d1Q_Qhs4O0a7bgcOusOgIeaP85yMBkI1zg4tpPiumgCsx-LYvNcMEqwzPCxvvp9jVrxyjce959BSR-nwEksDSUxLFUh3HXd8PNeUiFcyHS8qoUhAEaIjTOEsBrnUhggu8OOAJVyYUYITAgzba0BPUyvJMnyGsFE_Tis5MJCxMTAgNhdHgKiHi8TVtI9ZoRSY1ebg9w-JT-jXHaKNMaZUpa2W20f1CrHDsGesEwmWVy7LatjDujBFJ18jeNvaRMEfsjw-V6Xw-kwBCLJUefEwbnTrDLV4H8BZ0Sb3zfzz5Bm1Ho0Ff9l-Gbxdox96qssnoJWqV33N9BbiljK-rgfkLoLTbTA
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3dS8MwEA86QQQRv52fEXyttk2yJY-ijvk1fNhAn0LaJEzQttgN_PO9NO3Qh7EHH0t7aXvX3P0uvfsFoQsT2xSicBSwrmEBNTwMEldFCI5PhDphmldVlc-DTn9EH15ZU01Y1mWVLoe2niii8tVuchfaNhVxV5EjtQJkAdld7HqpGKUxXUYrjIsKI4Vv_cYZE06Fp0xlncDJNE0884b5E57-kJfOh6BVKOptoo0aQ-Jrb_QttGSybbTuF-Cw7yvaQeEw_35PAWPj3OJinJfFGGAlBtf2qUocYJXhaeHSfY19-8ouGvXuhjf9oN4eIUgh8kwCRbVJkm4UCUMY15xGcEgoUQpyAANpGqMa0FoXErg4TGKWMmUFBxvEIVxjLNlDrSzPzAHCSjGtKzYznlKRWgEXcmvAU0LCExnSRrTRikxr7nC3hcWHjGqK0UaZ0ilT1spso8uZWOHJMxYJiN8ql5Nq1cL6LUYkWSB73thHwhRx_z1UZvJpKQGDOCY9eJk22veGmz0OwC0YkoSH_7jzGVp9ue3Jp_vB4xFac2eqWjJyjFqTr6k5AdQySU6r7_IHUa_adQ
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Toxicity+of+phosphate+enemas+-+an+updated+review&rft.jtitle=Clinical+toxicology+%28Philadelphia%2C+Pa.%29&rft.au=Hamilton+Smith%2C+Rosa&rft.au=Eddleston%2C+Michael&rft.au=Bateman%2C+D.+Nicholas&rft.date=2022-06-03&rft.pub=Taylor+%26+Francis&rft.issn=1556-3650&rft.eissn=1556-9519&rft.volume=60&rft.issue=6&rft.spage=672&rft.epage=680&rft_id=info:doi/10.1080%2F15563650.2022.2054424&rft.externalDBID=0YH&rft.externalDocID=2054424
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1556-3650&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1556-3650&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1556-3650&client=summon